Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Most Effective Treatment Strategy for Diabetic Macular Edema
2012-003652-36Phase 3Active
- Sponsor
- Het Oogziekenhuis Rotterdam
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab in diabetic macular edema (DME) (2 arms), sponsored by Het Oogziekenhuis Rotterdam. Primary endpoint: Proportion of failures at 72 weeks. Started Sep 2012; status: active.
02
Drugs
bevacizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2012-003652-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003652-36.